Fusion protein having enhanced in vivo activity of...

Details Fusion protein having enhanced in vivo activity of... Fusion protein having enhanced in vivo activity of...

C - Chemistry, Metallurgy

12

N

C12N 15/10 (2006.01) A61K 38/18 (2006.01) C07K 14/505 (2006.01) C07K 14/52 (2006.01) C07K 19/00 (2006.01) C12N 15/62 (2006.01)

Patent

CA 2394572

The present invention relates to a fusion protein having enhanced in vivo activity of erythropoietin wherein a carboxy terminal peptide fragment of thrombopoietin is fused with the carboxy terminal of human erythropoietin. This fusion protein has highly enhanced in vivo half-life due to increased carbohydrate content without loss of the inherent activity of erythropoietin, and does not cause any antigenicity when applied to the human body.

Affiliated with

Also associated with

Rating

Fusion protein having enhanced in vivo activity of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fusion protein having enhanced in vivo activity of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion protein having enhanced in vivo activity of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1623976